CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01709435
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:24.070126+00:00
Published At: 2023-12-21T00:00:00+00:00
Record Updated At: 2023-12-22
Results Posted At: 2023-12-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Malignant Solid Neoplasm", "Recurrent Melanoma", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Thyroid Gland Carcinoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm", "Thyroid Gland Medullary Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-22"
protocolSection.identificationModule.nctId: "NCT01709435"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-12-21"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.